חוב כולל של החברה: meipharma.com (MEIP)

The share price history of MEI Pharma, Inc. (MEIP) reflects a period of systematic wind-down and liquidation of current developments aimed at transferring assets to external partners. The business previously relied on creating safe inhibitors for elderly patients, which expanded the scope of therapy. The individual debt metric stands at 0.00, while the absence of proprietary plants due to outsourcing minimizes the company's capital expenditures.

This indicator aggregates the total credit obligations of the issuer, reflecting the level of financial leverage and the business's dependence on borrowed capital. In biopharmaceuticals, MEI Pharma, Inc. (MEIP) debt load determines the cost of financing R&D projects, as the success of developing blood cancer drugs does not depend on market cycles. By analyzing the debt load trajectory, an investor can assess the company's resilience regarding the conditions for raising funds for clinical trials.